All In Biotech

Drug Trial Radar · NCT02596126

Secondary Prevention of Cardiovascular Disease in the Elderly Trial

Last checked: Nov 20, 2026Latest source record: May 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,499 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,499

Actual

Start

Jul 2016

Primary completion

Oct 31, 2021

Study completion Mar 31, 2022

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Charite University, Berlin, Germany; Centre Hospitalier Universitaire de Besancon; Wroclaw Medical University; Semmelweis University; General University Hospital, Prague; Servicio Madrileño de Salud, Madrid, Spain; London School of Hygiene and Tropical Medicine; Ferrer Internacional S.A.; Istituto Di Ricerche Farmacologiche Mario Negri
First posted
Nov 4, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy of a polypill strategy containing aspirin (100 mg), ramipril (2.5, 5 or 10 mgs), and atorvastatin (40 mgs) compared with the standard of care (usual care according to the local clinical practices at each participating country) in secondary prevention of major cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, and urgent revascularization) in elderly patients with a recent myocardial infarction.

Conditions

  • Myocardial Infarction
  • Cardiovascular Disease

Interventions

  • Cardiovascular PolypillDrug

    Cardiovascular Polypill contains Aspirin, Atorvastatin and Ramipril. Participants will receive one of the following cardiovascular polypill: (A) Aspirin 100 mg, Atorvastatin 40mg, and Ramipril (2.5 mg, or 5 mg, or 10mg). or (B) Aspirin 100 mg, Atorvastatin 20mg, and Ramipril (2.5 mg, or 5 mg, or 10mg).

  • Treatment Prevention for Secondary CVDrug

    ESC Guideline (2013 guideline on management of stable coronary disease) recommended pharmacological treatment for event prevention.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major Cardiovascular Adverse Events (MACE)Time frame: Up to 5 years

Locations

113 sites in 7 countries. Site status is shown where the registry gives one.

  • Nemocnice Rudolfa a Stefanie Benešov

    Benešov, Czechia

  • Nemocnice Jihlava

    Jihlava, Czechia

  • Krajská necmonice Liberec

    Liberec, Czechia

  • Fakultní nemocnice Olomouc

    Olomouc, Czechia

  • Nemocnice Slaný

    Slaný, Czechia

  • Nemocnice Podlesí

    Třinec, Czechia

  • Všeobecná fakultní nemocnice v Praze

    Prague, Prague, Czechia

  • Fakultní nemocnice Královské Vinohrady

    Prague, Praha 10, Czechia

  • Nemocnice Na Homolce

    Prague, Praha 5, Czechia

  • Centre Hospitalier Universitaire d'Angers

    Angers, France

  • Centre Hospitalier Régional Universitaire de Besançon

    Besançon, France

  • Centre Hospitalier Universitaire de Lyon

    Bron, France

  • Centre Hospitalier Universitaire de Caen

    Caen, France

  • Centre Hospitalier Metropole Savoie

    Chambéry, France

  • Centre Hospitalier Universitaire Henri Mondor

    Créteil, France

  • Centre Hospitalier Universitaire de Dijon

    Dijon, France

  • Centre Hospitalier Universitaire de Grenoble

    Grenoble, France

  • Centre Hospitalier Régional et Universitaire de Lille

    Lille, France

  • Centre Hospitalier St Joseph St Luc

    Lyon, France

  • Centre Hospitalier Universitaire de Nice

    Nice, France

  • Hôpital Bichât

    Paris, France

  • Centre hospitalier Universitaire de Bordeaux

    Pessac, France

  • Centre Hospitalier Universitaire de Toulouse

    Toulouse, France

  • GLG Fachklinik Wolletzsee GmbH

    Angermünde, Germany

  • AVK Vivantes Rehabilitation GmbH

    Berlin, Germany

  • DRK- Kliniken Berlin/ Köpenick

    Berlin, Germany

  • Maria Heimsuchung Caritas-Klinik Pankow

    Berlin, Germany

  • Jüdisches Krankenhaus

    Berlin, Germany

  • Charité - Universitätsmedizin Berlin, Centrum für Schlaganfallforschung (CSB)

    Berlin, Germany

  • Vivantes Humboldt Klinikum

    Berlin, Germany

  • Vivantes Klinikum Spandu

    Berlin, Germany

  • DRK Klinik Berlin Westend

    Berlin, Germany

  • GK Havelhöhe

    Berlin, Germany

  • Gesundheitszentrum Bitterfeld /Wolfen GmbH

    Bitterfeld-Wolfen, Germany

  • Mediclin Reha-Zentrum Spreewald Fachklinik für innere Medizin

    Burg, Germany

  • MediClin Herzzentrum Coswig

    Coswig, Germany

  • Klinik am See, Rehabilitationszentrum für innere Medizin

    Rüdersdorf, Brandenburg, Germany

  • Immanuel Klinikum Bernau Herzzentrum Brandenburg

    Bernau, State of Berlin, Germany

  • Medical Park Berlin Humboldtmühle

    Tegel, State of Berlin, Germany

  • Brandenburgklinik Berlin-Brandenburg GmbH, Haus Brandenburg/ Kardiologie

    Waldsiedlung, State of Berlin, Germany

Showing 40 of 113 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.